-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Click on the blue letters to pay attention to the secretion of pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) caused by peripheral inflammation.
These inflammations Factors can enter the central nervous system through the blood-brain barrier (BBB), activate microglia and polarize them into the pro-inflammatory M1 phenotype
.
There are many evidences that M1 type microglia are involved in the occurrence and development of depression
.
The nanomaterial drug delivery system can deliver the right dose of medicine to the right place at the right time
.
Light-activated melatonin release nanoparticles are melatonin encapsulated in conversion nanoparticles (UZPM) that can sense changes in pH, and then polyethylene glycol (PEG, which can improve biocompatibility), UZPM, and melatonin Fused together
.
The rapid release of melatonin can be achieved under infrared stimulation.
This nanomaterial drug delivery system is called UZPM
.
On December 12, 2021, Professor Wang Xiaolei from the Institute of Translational Medicine of Nanchang University and Professor Pan Bingxing from the School of Life Sciences jointly modified the UZPM system and upgraded it to CAR-M-UZPM, which can effectively inhibit the inflammatory activity of M1 type microglia.
Play an antidepressant effect
.
Researchers have made improvements on the basis of UZPM, using aldehyde-modified CTLA-4 as the chimeric antigen receptor (CAR) targeting group, and modifying the surface of macrophages through aldehyde/hydroxylamine condensation to precisely target M1 type small cells.
Glial cells form CAR-M-UZPM particles
.
When the above particles are combined with CD86, the surface costimulatory factor of M1 type microglia, it can inhibit the inflammatory signal pathway.
If irradiated under 980 nm infrared light, the structure of ZIF-8 will be triggered to release melatonin and cause photosensitivity.
Fast anti-inflammatory effect
.
They found through in vitro cell experiments that melatonin can protect microglia from lipopolysaccharide-induced inflammation: inhibit the release of pro-inflammatory factors (IL-6 and TNF-α), while promoting anti-inflammatory factors (IL-4).
And IL-10) secretion
.
At the same time, it can promote the conversion of M1 type microglia to M2 type microglia
.
Further in vitro cell experiments show that CAR-M-UZPM particles are not cytotoxic and cannot pass the blood-brain barrier without inflammation
.
However, CAR-M-UZPM particles can reach the hippocampus of mice after the inflammation caused by lipopolysaccharide increases the permeability of the blood-brain barrier
.
Intraperitoneal injection of high doses of LPS for 10 consecutive days can cause depression-like behavior in mice.
CAR-M-UZPM injection can inhibit pro-inflammatory factors, promote the release of anti-inflammatory factors, and significantly improve depression-like behavior disorders
.
Studies have shown that depression caused by inflammation is related to the decreased expression of hippocampal brain-derived neurotrophic factor (BDNF), and antidepressants can significantly increase the expression of BDNF to play a therapeutic role
.
Researchers found that CAR-M-UZPM treatment can promote the expression of hippocampal BDNF and reduce the expression of inflammation-related proteins
.
CAR-M-UZPM treatment can not only alleviate the abnormal expression of neurotrophic factors in the hippocampus caused by inflammation, but also alleviate the excessive excitement of amygdala projection neurons caused by inflammation
.
In general, this article integrates materials science into basic medicine, which not only realizes the expansion of nanoparticle research and application, but also solves the world problem of basic medicine manipulating microglia.
.
CAR-M-UZPM targeting M1 microglia can effectively reduce the inflammatory response caused by lipopolysaccharide, promote the expression of BDNF in the hippocampus, inhibit the excessive excitement of amygdala projection neurons, and exert an antidepressant effect
.
[References] 1.
https://doi.
org/10.
1002/adma.
202108525 The pictures in the text are from the references
These inflammations Factors can enter the central nervous system through the blood-brain barrier (BBB), activate microglia and polarize them into the pro-inflammatory M1 phenotype
.
There are many evidences that M1 type microglia are involved in the occurrence and development of depression
.
The nanomaterial drug delivery system can deliver the right dose of medicine to the right place at the right time
.
Light-activated melatonin release nanoparticles are melatonin encapsulated in conversion nanoparticles (UZPM) that can sense changes in pH, and then polyethylene glycol (PEG, which can improve biocompatibility), UZPM, and melatonin Fused together
.
The rapid release of melatonin can be achieved under infrared stimulation.
This nanomaterial drug delivery system is called UZPM
.
On December 12, 2021, Professor Wang Xiaolei from the Institute of Translational Medicine of Nanchang University and Professor Pan Bingxing from the School of Life Sciences jointly modified the UZPM system and upgraded it to CAR-M-UZPM, which can effectively inhibit the inflammatory activity of M1 type microglia.
Play an antidepressant effect
.
Researchers have made improvements on the basis of UZPM, using aldehyde-modified CTLA-4 as the chimeric antigen receptor (CAR) targeting group, and modifying the surface of macrophages through aldehyde/hydroxylamine condensation to precisely target M1 type small cells.
Glial cells form CAR-M-UZPM particles
.
When the above particles are combined with CD86, the surface costimulatory factor of M1 type microglia, it can inhibit the inflammatory signal pathway.
If irradiated under 980 nm infrared light, the structure of ZIF-8 will be triggered to release melatonin and cause photosensitivity.
Fast anti-inflammatory effect
.
They found through in vitro cell experiments that melatonin can protect microglia from lipopolysaccharide-induced inflammation: inhibit the release of pro-inflammatory factors (IL-6 and TNF-α), while promoting anti-inflammatory factors (IL-4).
And IL-10) secretion
.
At the same time, it can promote the conversion of M1 type microglia to M2 type microglia
.
Further in vitro cell experiments show that CAR-M-UZPM particles are not cytotoxic and cannot pass the blood-brain barrier without inflammation
.
However, CAR-M-UZPM particles can reach the hippocampus of mice after the inflammation caused by lipopolysaccharide increases the permeability of the blood-brain barrier
.
Intraperitoneal injection of high doses of LPS for 10 consecutive days can cause depression-like behavior in mice.
CAR-M-UZPM injection can inhibit pro-inflammatory factors, promote the release of anti-inflammatory factors, and significantly improve depression-like behavior disorders
.
Studies have shown that depression caused by inflammation is related to the decreased expression of hippocampal brain-derived neurotrophic factor (BDNF), and antidepressants can significantly increase the expression of BDNF to play a therapeutic role
.
Researchers found that CAR-M-UZPM treatment can promote the expression of hippocampal BDNF and reduce the expression of inflammation-related proteins
.
CAR-M-UZPM treatment can not only alleviate the abnormal expression of neurotrophic factors in the hippocampus caused by inflammation, but also alleviate the excessive excitement of amygdala projection neurons caused by inflammation
.
In general, this article integrates materials science into basic medicine, which not only realizes the expansion of nanoparticle research and application, but also solves the world problem of basic medicine manipulating microglia.
.
CAR-M-UZPM targeting M1 microglia can effectively reduce the inflammatory response caused by lipopolysaccharide, promote the expression of BDNF in the hippocampus, inhibit the excessive excitement of amygdala projection neurons, and exert an antidepressant effect
.
[References] 1.
https://doi.
org/10.
1002/adma.
202108525 The pictures in the text are from the references
